Royal Bank of Canada »

Rapport Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2024-09-30 $32k 1.5k 22.01
2024-06-30 $5.0k 225 22.22

More positions owned by Royal Bank of Canada

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Toronto Dominion Bk Ont Com New (TD)
Rbc Cad (RY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Core S&p500 Etf (IVV)
Bk Nova Cad (BNS)
Ishares Tr Russell 2000 Etf (IWM)
Bank Of Montreal Cadcom (BMO)
JPMorgan Chase & Co. (JPM)
Enbridge (ENB)
Cibc Cad (CM)

View all positions for Royal Bank of Canada

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics